• 1.

    Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:292298.

    • Search Google Scholar
    • Export Citation
  • 2.

    Besarab A, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584590.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Drüeke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:20712084.

  • 4.

    Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:20852098.

  • 5.

    Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:20192032.

  • 6.

    Macdougall IC, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 7.

    Macdougall IC, et al. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2016; 89:2839.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. Am J Kidney Dis 2017; 69:815826.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Locatelli F, et al. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 2017; 45:187199.

KDIGO Quo Vadis: Anemia

  • 1 Iain C. Macdougall, MD is Consultant Nephrologist and Professor of Clinical Nephrology, Department of Renal Medicine at King’s College Hospital, London, United Kingdom.
Restricted access

It is now seven years since the KDIGO guideline on anemia management in chronic kidney disease (CKD) was published in August 2012 (1). To accuse KDIGO of being lazy and idle in generating any updates or revisions would be inappropriate on two accounts.

First, and most important, there has really not been enough truly robust scientific data that would dramatically alter the evidence base from the previous version of the anemia guideline, in which the four NEJM “biggies” on erythropoiesis stimulating agent (ESA) therapy were reviewed and critiqued by the evidence review team: US Normal Hematocrit

Save